Non-Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia – Landscape & Forecast – Disease Landscape & Forecast
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL) therapy market. Key therapies expected to fuel growth are the CAR T-cell therapies Yescarta (Gilead), Kymriah (Novartis), Tecartus (Gilead), and Breyanzi (Bristol Myers Squibb), targeted agents Polivy (Roche), Monjuvi / Minjuvi (MorphoSys / Incyte), Tazverik (Epizyme), Brukinsa (BeiGene), Zynlonta (ADC Therapeutics), as well as the approval of first-in-class bispecific antibody, Lunsumio (Roche). In addition, combinations incorporating Imbruvica (Janssen / AbbVie), Calquence (AstraZeneca), and Venclexta / Venclyxto (AbbVie / Roche) will enter the CLL market, resulting in a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of the other bispecific antibodies glofitamab (Roche) and epcoritamab (Genmab / AbbVie) and the noncovalent BTK inhibitor pirtobrutinib (Loxo Oncology / Eli Lilly) will further fragment the DLBCL, FL, and CLL / SLL patient settings, creating intense competition.
Questions Answered
- What is the size of clinically and commercially relevant drug-treatable NHL / CLL populations, and how will drug-treatment rates change over the 2021-2031 forecast period, by geography?
- What is the expected market impact of recent drug approvals and label expansions on the various NHL / CLL patient populations?
- Which emerging therapies are the most promising in NHL / CLL, and what patient populations will they target? What will be their impact on the NHL / CLL market?
- What factors are driving growth in the NHL / CLL market? Which drug class will dominate the treatment of NHL / CLL?
Content Highlights
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.
Epidemiology: Diagnosed incidence of NHL by country; drug-treatable and drug-treated cases segmented by subtype (follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia / small lymphocytic leukemia) and line of therapy.
Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL / SLL, DLBCL, and MCL.
Emerging therapies: Phase III / PR: 11 drugs.
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key findings on NHL / CLL
- Key updates
- June 2023
- March 2023
- January 2023
- Q4 2022
- December 2022
- November 2022
- Q3 2022
- July 2022
- Q2 2022
- June 2022
- May 2022
- May 2022
- April 2022
- Market outlook
- Key findings
- Market share of drug classes for non-Hodgkin's lymphoma: 2021
- Market share of drug classes for non-Hodgkin's lymphoma: 2031
- Positioning of key therapies in chronic lymphocytic leukemia / small lymphocytic lymphoma in the United States: 2021-2031
- Positioning of key therapies in diffuse large B-cell lymphoma in the United States: 2021-2031
- Positioning of key therapies in follicular lymphoma in the United States: 2021-2031
- Positioning of key therapies in mantle cell lymphoma in the United States: 2021-2031
- Non-Hodgkin's lymphoma SWOT analysis
- Current therapies with sales potential in non-Hodgkin's lymphoma: population positioning
- Emerging therapies with sales potential in non-Hodgkin's lymphoma: population positioning
- Market drivers and constraints
- What factors are driving the market for NHL?
- What factors are constraining the market for NHL?
- Drug-treatable population share and major-market sales share for CLL / SLL: 2021
- Drug-treatable population share and major-market sales share for CLL / SLL: 2031
- Drug-treatable population share and major-market sales share for DLBCL: 2021
- Drug-treatable population share and major-market sales share for DLBCL: 2031
- Drug-treatable population share and major-market sales share for FL: 2021
- Drug-treatable population share and major-market sales share for FL: 2031
- Drug-treatable population share and major-market sales share for MCL: 2021
- Drug-treatable population share and major-market sales share for MCL: 2031
- Major-market non-Hodgkin's lymphoma sales by subpopulation: 2021-2031
- Key non-Hodgkin's lymphoma therapies with major-market sales exceeding $1.0 billion in 2031
- Segment-specific trends
- Patient-share dynamics of key drug classes in first-line CLL / SLL in the United States: 2021-2031
- Patient-share dynamics of key therapies in first-line CLL / SLL in the United States: 2021-2031
- Sales of key therapies for first-line CLL / SLL in the United States: 2021-2031
- Patient-share dynamics of key therapies in second-line CLL / SLL in the United States: 2021-2031
- Patient-share dynamics of key therapies in third-line CLL / SLL in the United States: 2021-2031
- Sales of key therapies for second-line CLL / SLL in the United States: 2021-2031
- Sales of key therapies for third-line CLL / SLL in the United States: 2021-2031
- Patient-share dynamics of key therapies in first-line DLBCL in the United States: 2021-2031
- Sales of key therapies for first-line DLBCL in the United States: 2021-2031
- Patient-share dynamics of key therapies in second-line DLBCL in the United States: 2021-2031
- Patient-share dynamics of key therapies in third-line DLBCL in the United States: 2021-2031
- Sales of key therapies for second-line DLBCL in the United States: 2021-2031
- Sales of key therapies for third-line DLBCL in the United States: 2021-2031
- Patient-share dynamics of key therapies in first-Line FL in the United States: 2021-2031
- Sales of key therapies for first-line FL in the United States: 2021-2031
- Patient-share dynamics of key therapies in second-line FL in the United States: 2021-2031
- Patient-share dynamics of key therapies in third-line FL in the United States: 2021-2031
- Sales of key therapies for second-line FL in the United States: 2021-2031
- Sales of key therapies for third-line FL in the United States: 2021-2031
- Patient-share dynamics of key therapies in first-line MCL in the United States: 2021-2031
- Sales of key therapies for first-line MCL in the United States: 2021-2031
- Patient-share dynamics of key therapies in second-Line MCL in the United States: 2021-2031
- Patient-share dynamics of key therapies in third-line MCL in the United States: 2021-2031
- Sales of key therapies for second-line MCL in the United States: 2021-2031
- Sales of key therapies for third-line MCL in the United States: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Disease pathophysiology
- Select risk factors associated with non-Hodgkin's lymphoma
- International prognostic index scoring for NHL patients of all ages
- Revised international prognostic index score in patients treated with R-CHOP
- Select biomarkers for non-Hodgkin's lymphoma subpopulations predicting clinical outcome
- Staging and classification
- Staging of non-Hodgkin's lymphoma
- Revised Ann Arbor staging system for primary nodal lymphomas
- The Binet staging system for CLL / SLL
- The Rai staging system for CLL / SLL
- Normal B-cell development and cellular origin of B-cell malignancies
- Key pathways and drug targets
- Key drug targets for non-Hodgkin's lymphoma
- Select drug targets currently exploited or in development for non-Hodgkin's lymphoma and chronic lymphocytic leukemia
- Immune checkpoint activation and pathways
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition, methods, and sources used
- Diagnosed incident cases of NHL/CLL: 2021-2031
- Disease definition, methods, and sources used
- Diagnosed incident cases of de novo DLBCL: 2021-2031
- Disease definition, methods, and sources used
- Diagnosed incident cases of transformed incidence from FL to DLBCL: 2021-2031
- Disease definition, methods, and sources used
- Diagnosed incident cases of transformed incidence from CLL to DLBCL: 2021-2031
- FL patient flow
- Drug-treatable cases of FL: 2021-2031
- DLBCL drug-treatable population
- DLBCL patient flow
- Drug-treatable cases of DLBCL: 2021-2031
- MCL drug-treatable population
- MCL patient flow
- Drug-treatable cases of MCL: 2021-2031
- CLL / SLL drug-treatable population
- CLL / SLL patient flow
- Drug-treatable cases of CLL/SLL: 2021-2031
- Drug-treated cases of FL: 2021-2031
- Drug-treated cases of DLBCL: 2021-2031
- Drug-treated cases of MCL: 2021-2031
- Drug-treated cases of CLL/SLL: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for NHL
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for NHL
- Current treatments used for NHL
- Market events impacting the use of key current therapies in NHL
- Ongoing clinical development of rituximab (Rituxan / MabThera)
- Key ongoing clinical trials of rituximab (Rituxan / MabThera) in the treatment of NHL
- Expert insight: rituximab (Rituxan / MabThera)
- Key results from select clinical trials investigating Gazyva / Gazyvaro for the treatment of NHL
- Ongoing clinical development of Gazyva / Gazyvaro
- Key ongoing clinical trials of Gazyva / Gazyvaro in the treatment of NHL
- Expert insight: Gazyva / Gazyvaro
- Key results from select clinical trials investigating Monjuvi / Minjuvi for the treatment of NHL
- Ongoing clinical development of Monjuvi / Minjuvi
- Key ongoing clinical trials of Monjuvi / Minjuvi in the treatment of NHL
- Expert insight: Monjuvi / Minjuvi
- Expert insight: Arzerra
- Key results from select clinical trials investigating Polivy for the treatment of NHL
- Ongoing clinical development of Polivy
- Key ongoing clinical trials of Polivy in the treatment of NHL
- Expert insight: Polivy
- Key results from select clinical trials investigating Zynlonta for the treatment of NHL
- Ongoing clinical development of Zynlonta
- Key ongoing clinical trials of Zynlonta in the treatment of NHL
- Expert insight: Zynlonta
- Key results from select clinical trials investigating Venclexta / Venclyxto for the treatment of NHL
- Ongoing clinical development of Venclexta / Venclyxto
- Key ongoing clinical trials of Venclexta / Venclyxto in the treatment of NHL
- Expert insight: Venclexta / Venclyxto
- Key results from select clinical trials investigating lenalidomide (Revlimid) for the treatment of NHL
- Ongoing clinical development of lenalidomide (Revlimid)
- Key ongoing clinical trials of lenalidomide (Revlimid) in the treatment of NHL
- Expert insight: bortezomib (Velcade)
- Key results from select clinical trials investigating Imbruvica for the treatment of NHL
- Ongoing clinical development of Imbruvica
- Key ongoing clinical trials of Imbruvica in the treatment of NHL
- Expert insight: Imbruvica
- Key results from select clinical trials investigating Calquence for the treatment of NHL
- Ongoing clinical development of Calquence
- Key ongoing clinical trials of Calquence in the treatment of NHL
- Expert insight: Calquence
- Key results from select clinical trials investigating Brukinsa for the treatment of NHL
- Ongoing clinical development of Brukinsa
- Key ongoing clinical trials of Brukinsa in the treatment of NHL
- Expert insight: Brukinsa
- Key results from select clinical trials investigating Jaypirca for the treatment of NHL
- Ongoing clinical development of Jaypirca
- Key ongoing clinical trials of Jaypirca in the treatment of NHL
- Expert insight: Jaypirca
- Key results from select clinical trials investigating Zydelig for the treatment of NHL
- Ongoing clinical development of Zydelig
- Key ongoing clinical trials of Zydelig in the treatment of NHL
- Expert insight: Zydelig
- Key results from select clinical trials investigating Aliqopa for the treatment of NHL
- Ongoing clinical development of Aliqopa
- Key ongoing clinical trials of Aliqopa in the treatment of NHL
- Expert insight: Aliqopa
- Key results from select clinical trials investigating Copiktra for the treatment of NHL
- Ongoing clinical development of Copiktra
- Key ongoing clinical trials of Copiktra in the treatment of NHL
- Expert insight: Copiktra
- Expert insight: Bendamustine
- Clinical development of Pixuvri
- Key results from select clinical trials investigating Yescarta for the treatment of NHL
- Ongoing clinical development of Yescarta
- Key ongoing clinical trials of Yescarta in the treatment of NHL
- Expert insight: Yescarta
- Key results from select clinical trials investigating Kymriah for the treatment of NHL
- Ongoing clinical development of Kymriah
- Key ongoing clinical trials of Kymriah in the treatment of NHL
- Expert insight: Kymriah
- Tecartus
- Key results from select clinical trials investigating Tecartus for the treatment of NHL
- Ongoing clinical development of Tecartus
- Key ongoing clinical trials of Tecartus in the treatment of NHL
- Expert insight: Tecartus
- Key results from select clinical trials investigating Breyanzi for the treatment of NHL
- Ongoing clinical development of Breyanzi
- Key ongoing clinical trials of Breyanzi in the treatment of NHL
- Expert insight: Breyanzi
- Key results from select clinical trials investigating Keytruda for the treatment of NHL
- Ongoing clinical development of Keytruda
- Key ongoing clinical trials of Keytruda in the treatment of NHL
- Expert insight: Keytruda
- Tazverik
- Key results from select clinical trials investigating Tazverik for the treatment of NHL
- Ongoing clinical development of Tazverik
- Key ongoing clinical trials of Tazverik in the treatment of NHL
- Expert insight: Tazverik
- Key results from select clinical trials investigating Xpovio for the treatment of NHL
- Ongoing clinical development of Xpovio / Nexpovio
- Key ongoing clinical trials of Xpovio / Nexpovio in the treatment of NHL
- Expert insight: Xpovio / Nexpovio
- Key results from select clinical trials investigating Lunsumio for the treatment of NHL
- Ongoing clinical development program of Lunsumio
- Key ongoing clinical trials of Lunsumio in the treatment of NHL
- Expert insight: Lunsumio
- Medical practice
- First-line CLL / SLL drug-treatable population
- First-line DLBCL drug-treatable population
- First-line FL drug-treatable population
- First-line MCL drug-treatable population
- Relapsed / refractory CLL / SLL drug-treatable population
- Relapsed / refractory DLBCL drug-treatable population
- Relapsed / refractory FL drug-treatable population
- Relapsed / refractory MCL drug-treatable population
- Patient characteristics influencing drug selection in NHL
- Treatment decision tree for FL: United States
- Treatment decision tree for CLL / SLL: United States
- Treatment decision tree for DLBCL: United States
- Treatment decision tree for MCL: United States
- Treatment decision tree for FL: Europe
- Treatment decision tree for CLL / SLL: Europe
- Treatment decision tree for DLBCL: Europe
- Treatment decision tree for MCL: Europe
- Treatment decision tree for FL: Japan
- Treatment decision tree for CLL / SLL: Japan
- Treatment decision tree for DLBCL: Japan
- Treatment decision tree for MCL: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in non-Hodgkin's lymphoma
- Top unmet needs in non-Hodgkin's lymphoma: current and future attainment
- Expert insight: unmet need in non-Hodgkin's lymphoma
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for NHL
- Estimated market authorization dates of key emerging therapies for the treatment of NHL
- Key results from select clinical trials investigating Enzastaurin for the treatment of NHL
- Key ongoing clinical trials of Enzastaurin in the treatment of NHL
- Analysis of the clinical development program for Enzastaurin
- Expert insight: Enzastaurin
- Expectations for market authorization and sales opportunity of Enzastaurin in NHL
- Key results from select clinical trials investigating zilovertamab for the treatment of NHL
- Key ongoing clinical trials of zilovertamab in the treatment of NHL
- Analysis of the clinical development program for zilovertamab
- Expectations for market authorization and sales opportunity of zilovertamab in NHL
- Key results from select clinical trials investigating odronextamab for the treatment of NHL
- Key ongoing clinical trials of odronextamab in the treatment of NHL
- Analysis of the clinical development program for odronextamab
- Expectations for market authorization and sales opportunity of odronextamab in NHL
- Key results from select clinical trials investigating Adcetris for the treatment of NHL
- Key ongoing clinical trials of Adcetris in the treatment of NHL
- Analysis of the clinical development program for Adcetris
- Expert insight: Adcetris
- Expectations for market authorization and sales opportunity of Adcetris in NHL
- Key results from select clinical trials investigating zilovertamab vedotin for the treatment of NHL
- Key ongoing clinical trials of zilovertamab vedotin in the treatment of NHL
- Analysis of the clinical development program for zilovertamab vedotin
- Expectations for market authorization and sales opportunity of zilovertamab vedotin
- Key results from select clinical trials investigating Opdivo for the treatment of NHL
- Key ongoing clinical trials of Opdivo in the treatment of NHL
- Analysis of the clinical development program for Opdivo
- Expert insight: Opdivo
- Expectations for market authorization and sales opportunity of Opdivo in NHL
- Zandelisib
- Key results from select clinical trials investigating zandelisib for the treatment of NHL
- Analysis of the clinical development program for zandelisib
- Key ongoing clinical trials of zandelisib in the treatment of NHL
- Expert insight: zandelisib
- Expectations for market authorization and sales opportunity of zandelisib in NHL
- Key results from select clinical trials investigating Onureg (oral azacitidine) for the treatment of NHL
- Key ongoing clinical trials of Onureg (oral azacitidine) in the treatment of NHL
- Analysis of the clinical development program for Onureg (oral azacitidine)
- Expert insight: Onureg (oral azacitidine)
- Expectations for market authorization and sales opportunity of Onureg (oral azacitidine) in NHL
- Early-phase pipeline analysis
- Select compounds in early-phase development for NHL
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in NHL: United States
- General reimbursement environment: United States
- Key market access considerations in NHL: EU5
- General reimbursement environment: EU5
- Key market access considerations in NHL: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Non-Hodgkin's lymphoma bibliography
- Key findings
Priyanka Sharma, M.B.A., Healthcare Research & Data Analyst, Oncology. Prior to joining this company, she was a knowledge management consultant with ZS Associates, where she was responsible for designing and conducting secondary research on disease markets and providing end-to-end support to pharmaceutical clients during products’ life cycle. She also worked at DelveInsight Business Research, where she conducted pharmaceutical market forecasting in multiple therapy areas for various clients. She holds a bachelor’s degree in pharmacy and an M.B.A. in pharmaceutical management from the University Institute of Applied Management Sciences at Panjab University in Chandigarh, India.
Harinder Kumar, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cancer and psychiatric epidemiology. Previously, Dr. Kumar worked with the government of Punjab, National Health Mission, India. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai. He holds a B.D.S. in dentistry from the National Dental College and Hospital in Punjab.